MTP-101C
Phase 2Small molecule
MTP-101C is one of 14 small molecule programs targeting Crohn Disease. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Crohn Disease
#DrugCompanyPhaseTrials
1Tremfya
Johnson & JohnsonApproved
Stelara
Johnson & JohnsonPhase 3
Skyrizi
AbbViePhase 3
JNJ-78934804
Johnson & JohnsonPhase 3
Xifaxan
SSalix
Phase 2
LY4395089
Eli LillyPhase 2
Mirikizumab - Intravenous (IV)
Eli LillyPhase 2
Mirikizumab - Subcutaneous (SC)
Eli LillyPhase 2
Icotyde
Johnson & JohnsonPreclinical
MTP-101C
UUniversity of Minnesota
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MTP-101C. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Minnesota